CEFEPIME FOR INJECTION POWDER FOR SOLUTION

Land: Kanada

Tungumál: enska

Heimild: Health Canada

Virkt innihaldsefni:

CEFEPIME (CEFEPIME HYDROCHLORIDE)

Fáanlegur frá:

APOTEX INC

ATC númer:

J01DE01

INN (Alþjóðlegt nafn):

CEFEPIME

Skammtar:

1G

Lyfjaform:

POWDER FOR SOLUTION

Samsetning:

CEFEPIME (CEFEPIME HYDROCHLORIDE) 1G

Stjórnsýsluleið:

INTRAMUSCULAR

Einingar í pakka:

IM:2.4ML/ IV:10ML/ IV INF:SEE PM.

Gerð lyfseðils:

Prescription

Lækningarsvæði:

FOURTH GENERATION CEPHALOSPORINS

Vörulýsing:

Active ingredient group (AIG) number: 0150504004; AHFS:

Leyfisstaða:

APPROVED

Leyfisdagur:

2009-02-16

Vara einkenni

PRODUCT MONOGRAPH
Cefepime for Injection
(cefepime hydrochloride)
1 g and 2 g cefepime per vial
Orchid Standard
Antibiotic
_Manufactured by: _
ORCHID HEALTHCARE
(A Division of Orchid Chemicals & Pharmaceuticals Ltd.)
Plot No: B3-B6 & B11-B14, SIPCOT Industrial Park,
Irungattukottai- 602 105, Sriperumbudur P.O.,
Kancheepuram District, INDIA.
_Manufactured for: _
APOTEX INC.
150 Signet Drive
Weston, ON, M9L 1T9
DATE OF PREPARATION
April 20, 2020
Control #: 234594
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.................................................. 3
SUMMARY PRODUCT INFORMATION
.............................................................................
3
INDICATIONS AND CLINICAL
USE...................................................................................
3
CONTRAINDICATIONS
........................................................................................................
5
WARNINGS AND PRECAUTIONS
......................................................................................
5
ADVERSE REACTIONS
........................................................................................................
8
DRUG INTERACTIONS
.......................................................................................................
10
DOSAGE AND ADMINISTRATION
...................................................................................
10
OVERDOSAGE
.....................................................................................................................
15
ACTION AND CLINICAL PHARMACOLOGY
................................................................. 15
STORAGE AND STABILITY
..............................................................................................
19
SPECIAL HANDLING INSTRUCTIONS
............................................................................
19
DOSAGE FORMS, COMPOSITION AND PACKAGING
.................................................. 19
PART II: SCIENTIFIC INFORMATION
.........................................................